Xue Xiao

Dr. Xue Xiao


Research Focus & Metrics

Academic Career Length

9Years (2018-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
26 November 2024 in Signal Transduction and Targeted Therapy
Verified
Journal Article
Open access
WDWanlin Dai
Wanlin Dai
XQXinbo Qiao
Xinbo Qiao
YFYuanyuan Fang
Yuanyuan Fang
RGRenhao Guo
Renhao Guo
PBPeng Bai
Peng Bai
DLDa Li
Da Li
Epigenetics governs a chromatin state regulatory system through five key mechanisms: DNA modification, histone modification, RNA modification, chromatin remodeling, and non-coding RNA regulation. These mechanisms and their associated enzymes convey genetic information independently of DNA base sequences, playing essential roles in organismal development and homeostasis. Conversely, disruptions in epigenetic landscapes critically influence the pathogenesis of various human diseases. This understanding has laid a robust theoretical groundwork for developing drugs that target epigenetics-modifying enzymes in pathological conditions. Over the past two decades, a growing array of small molecule drugs targeting epigenetic enzymes such as DNA methyltransferase, histone deacetylase, isocitrate dehydrogenase, and enhancer of zeste homolog 2, have been thoroughly investigated and implemented as therapeutic options, particularly in oncology. Additionally, numerous epigenetics-targeted drugs are undergoing clinical trials, offering promising prospects for clinical benefits. This review delineates the roles of epigenetics in physiological and pathological contexts and underscores pioneering studies on the discovery and clinical implementation of epigenetics-targeted drugs. These include inhibitors, agonists, degraders, and multitarget agents, aiming to identify practical challenges and promising avenues for future research. Ultimately, this review aims to deepen the understanding of epigenetics-oriented therapeutic strategies and their further application in clinical settings.

4 April 2024 in Molecular Cancer
Verified
Journal Article
Open access
PDF file
SYShichao Yang
Shichao Yang
CHCaden Hu
Caden Hu
XCXiaomei Chen
Xiaomei Chen
YTYi Tang
Yi Tang
JLJuanjuan Li
Juanjuan Li
YZYahui Zhu
Yahui Zhu
It is generally recognized that tumor cells proliferate more rapidly than normal cells. Due to such an abnormally rapid proliferation rate, cancer cells constantly encounter the limits of insufficient oxygen and nutrient supplies. To satisfy their growth needs and resist adverse environmental events, tumor cells modify the metabolic pathways to produce both extra energies and substances required for rapid growth. Realizing the metabolic characters special for tumor cells will be helpful for eliminating them during therapy. Cell death is a hot topic of long-term study and targeting cell death is one of the most effective ways to repress tumor growth. Many studies have successfully demonstrated that metabolism is inextricably linked to cell death of cancer cells. Here we summarize the recently identified metabolic characters that specifically impact on different types of cell deaths and discuss their roles in tumorigenesis.

15 March 2018 in BMC Complementary and Alternative Medicine
Verified
Journal Article
Open access
PDF file
XXXue Xiao
Xue Xiao
JZJuan Zou
Juan Zou
YFYin Fang
Yin Fang
YMYibo Meng
Yibo Meng
JCJun Qi Cheng
Jun Qi Cheng
YYYuan Yao
Yuan Yao
The anti-tumor activities of Natural compounds and their derivatives are of great interest to pharmaceutical industries. Fisetin is one of prospective natural compounds in this regard but unfortunately with poor hydrophilicity. The effects of unmodified and modified fisetin in cultured ovarian cancer cells were compared by transmission electronmicroscopy to determine apoptotic bodies, MTT assay to quantitate cell numbers, and fluorescence activated cell sorting analyse of various markers to determine the apoptotic state. In addition, the efficacy of fisetin and fisetin-micelles in vivo was determined by using immunocompromised mice. Apoptosis was measured by established markers using both western blot analysis and immunochemistry. Angiogenesis in a xenograft mouse model carring SKOV3 cells was evaluated by color Doppler ultrasound and immunohistochemistry. Multiple lines of evidence indicated that fisetin and fisetin micelles induce apoptosis in ovarian cancer cells in a dose-dependent manner. Histological analysis, terminal deoxynucleotidyltransferase-mediated nick-end labeling assay, western blot, immunohistochemical detection and microvessel density detection demonstrated that fisetin and fisetin micelles induced increased tumor apoptosis, proliferation suppression and antiangiogenesis activities. As far as we know, the present study is the first time to demonstrate the potency of both fisetin and fisetin micelles inducing apoptosis in ovarian cancer cells. Further studies will be needed to validate the therapeutic potential of fisetin and fisetin micelles in ovarian cancer treatment.

3 May 2024 in European Journal of Medicinal Chemistry
Verified
Journal Article
Closed access
ZLZihang Liu
Zihang Liu
LCLi Chen
Li Chen
JZJifa Zhang
Jifa Zhang
JYJun Yang
Jun Yang
XXXue Xiao
Xue Xiao
WMWuyu Mao
Wuyu Mao

1 July 2025 in Medcomm
Verified
Journal Article
Open access
JLJunzhi Liang
Junzhi Liang
XNXinni Na
Xinni Na
LMLingbo Meng
Lingbo Meng
LHLixia He
Lixia He
TSTing Shu
Ting Shu
XXXue Xiao
Xue Xiao
Ten‐eleven translocation (TET) family proteins are Fe(II)‐ and α‐ketoglutarate‐dependent dioxygenases, comprising three family members: TET1, TET2, and TET3. These enzymes drive DNA demethylation by sequentially oxidizing 5‐methylcytosine to 5‐hydroxymethylcytosine, 5‐formylcytosine, and 5‐carboxylcytosine. Through these reactions, TET proteins remodel the epigenetic landscape and interact with transcription factors and RNA polymerase II to regulate gene expression, cell lineage specification, and embryonic development. Mutations and dysregulation of TETs have been associated with the pathogenesis of various diseases, including the nervous system, immune system, and metabolic diseases, as well as cancers. Therapeutic modulation of TETs may be an effective strategy for the treatment of these diseases. Here, we provide a comprehensive overview of the mechanisms by which TET proteins mediate DNA demethylation and detail their biological functions. Additionally, we highlight recent advances in understanding the molecular mechanisms linking TET dysregulation to disease pathogenesis and explore their potential as therapeutic targets. This review supplements the current understanding of the critical role of epigenetic regulation in disease pathogenesis and further facilitates the rational design of targeted therapeutic agents for diseases associated with mutations and dysregulation of TETs.

16 December 2025 in Nature Genetics
Verified
Journal Article
Closed access
PDF file
SJShaoshuai Jiang
Shaoshuai Jiang
XLXinyi Liu
Xinyi Liu
ZZZhuheng Zhang
Zhuheng Zhang
MYMingzhu Yang
Mingzhu Yang
XZXing Zhu
Xing Zhu
JDJunjun Ding
Junjun Ding